Clinical Features of Corneal Adverse Events Associated With Trastuzumab Botidotin: Payload-Driven Epitheliopathy and

Yongyi Zhang1, Gege Tang1, Jingjie Zhang1

  • 1From the Department of Ophthalmology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.

Abstract

Insights

Trastuzumab botidotin, a HER2-targeted antibody-drug conjugate, caused ocular adverse events including corneal epitheliopathy and blurred vision in all patients studied. Early detection and collaboration are key for managing these side effects.

Area of Science:

  • Ophthalmology
  • Oncology
  • Pharmacology

Background:

  • HER2-targeted antibody-drug conjugates (ADCs) are effective cancer therapies.
  • Ocular adverse events (AEs), such as corneal epitheliopathy and blurred vision, are known side effects of ADCs.
  • Trastuzumab botidotin is a HER2-targeted ADC used for HER2-mutated or HER2-positive tumors.

Purpose of the Study:

  • To characterize the clinical features of corneal AEs associated with trastuzumab botidotin.
  • To evaluate the impact of trastuzumab botidotin on ocular surface parameters and corneal cellular structures.

Main Methods:

  • Retrospective case series of eight adult patients treated with trastuzumab botidotin.
  • Ophthalmic assessments included visual acuity, Ocular Surface Disease Index (OSDI), Schirmer's test, tear break-up time (TBUT), tear meniscus height (TMH), and corneal fluorescein staining (CFS).
  • In vivo confocal microscopy (IVCM) was used to examine corneal cellular structures and nerve damage.

Main Results:

  • All patients experienced corneal AEs, with visual impairment onset around 37 days and peak severity around 83 days.
  • Trastuzumab botidotin induced dry eye, significantly reducing tear production, TBUT, and TMH.
  • Corneal epitheliopathy manifested as pseudomicrocysts and vortex keratopathy, confirmed by IVCM showing cellular disorganization and neurotoxic damage to subbasal nerves.

Conclusions:

  • Trastuzumab botidotin is associated with significant visual impairment, corneal epitheliopathy, and nerve damage.
  • Prompt identification of these corneal AEs is crucial for managing patients on ADC therapy.
  • Collaboration between ophthalmologists and oncologists can improve patient outcomes and quality of life.

Related Concept Videos

Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
Cytotoxic Edema: Pathophysiology01:21

Cytotoxic Edema: Pathophysiology

Cytotoxic edema is a form of cerebral edema characterized by intracellular swelling of neurons, astrocytes, and other glial cells. It develops when the mechanisms responsible for maintaining ionic gradients across the cell membrane become impaired. Under normal physiological conditions, the sodium–potassium ATPase actively transports sodium ions out of the cell and potassium ions into the cell, preserving osmotic balance and enabling electrical signaling. This pump requires a continuous supply...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Drug Toxicity: Overview01:00

Drug Toxicity: Overview

Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...
Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...